

Maven Income and Growth VCT 5 PLC (the Company)
Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

Further to the Company's Issue of Equity announcement on 17 February 2026 in respect of the allotment of new Ordinary Shares under the Company's Offer for Subscription and following the admission to trading of those new Ordinary Shares, the following additional information is disclosed in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1 Details of the issuer		
a)	Name	Maven Income and Growth VCT 5 PLC
b)	LEI	213800DMF84841RMWX35
2 Details of the transferable securities admitted to trading		
a)	Name, type and identification code	Ordinary Shares of 10p each; ISIN: GB0002057536
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities admitted	13,399,375
d)	Total number of securities in issue following admission	253,641,645
e)	Fungibility	Fully fungible with existing Ordinary Shares
3 Admission details		
a)	Date of admission	18 February 2026
b)	Prospectus information	Prospectus: 2 October 2025 Supplementary: N/A Link: www.mavencp.com/vctoffer Company's webpage: www.mavencp.com/migvct5
c)	Coverage of notification	All admissions up to and including 18 February 2026
4 Contact details		
a)	Name and contact number	Company Secretary, Maven Capital Partners UK LLP Tel: 0141 306 7400

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lse.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEAKAPFSNKEFA